Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 71.18
lei 6406.05lei 71.18
lei 853.70
60 tablet
Free AirMail shipping Hot
lei 75.92
lei 4555.35lei 75.92
lei 284.49
30 tablet
Free AirMail shipping Hot
lei 80.66
lei 2419.92lei 80.66
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 85.41
lei 7687.31lei 85.41
lei 426.61
60 tablet
Free AirMail shipping Hot
lei 87.79
lei 5267.16lei 87.79
lei 142.12
30 tablet
Free AirMail shipping Hot
lei 90.15
lei 2704.64lei 90.15
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 102.02
lei 9182.11lei 102.02
lei 426.61
60 tablet
Free AirMail shipping Hot
lei 104.39
lei 6263.69lei 104.39
lei 142.12
30 tablet
Free AirMail shipping Hot
lei 106.76
lei 3202.91lei 106.76
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.